{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-012507","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2023-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.871926+00:00","generated_at":"2026-06-20T11:38:21.057919+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Aadi Bioscience amends supply agreement with Fresenius Kabi for Fyarro; term extended to March 2024","bullets":["Amendment extends contract term to March 31, 2024 (or later date if agreed).","Pricing and minimum purchase quantity obligations for Fyarro were updated and revised.","Agreement covers clinical and commercial manufacturing of Fyarro (sirolimus albumin-bound).","Contains customary biotech manufacturing terms; full agreement to be filed later."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-012507","json":"https://secwatch.observer/filing/0001193125-23-012507.json","markdown":"https://secwatch.observer/filing/0001193125-23-012507.md","text":"https://secwatch.observer/filing/0001193125-23-012507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312523012507/0001193125-23-012507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312523012507/d611917d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T11:38:21.057919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"46ec79991834f889fabadc2bbda9e2642c42ed38","claim":"Whitehawk Therapeutics, Inc. amended Amendment No.1 with Fresenius Kabi, LLC (effective 2023-01-17).","evidence_excerpt":"On January 17, 2023, Aadi Bioscience, Inc. (the “ Company ”) entered into Amendment No.1 (the “ Amendment ”) to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product (the “ Agreement ”) with Fresenius Kabi, LLC (“ Fresenius Kabi ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312523012507/0001193125-23-012507-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Fresenius Kabi, LLC"},{"label":"Effective","value":"2023-01-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}